

## “Development of a New Cancer Therapy: Translation of BCL2 Inhibition from Lab, to Trial, to Practice”

### Professor Andrew Roberts

*MB BS, FRACP, FRCPA, PhD*

Andrew Roberts is the Metcalf Chair of Leukaemia Research at the University of Melbourne, a clinical haematologist at the Royal Melbourne Hospital / Petermac and Head of Clinical Translation at the Walter & Eliza Hall Institute.

His major research interests are the development of new treatments for leukaemia, lymphoma and myeloma. He has been an academic leader in the clinical development of the novel targeted anti-cancer drug, venetoclax, from the research laboratory through clinical trials to registration.

He was President of the Haematology Society of Australia and New Zealand 2005 – 07, and Chair of the board of the Cancer Council Victoria 2013 – 17. He is a director of the Australasian Leukaemia and Lymphoma Group, and a member of Pharmaceutical Benefits Advisory Committee. In 2015, he was the first non-North American to serve as Scientific Co-Chair of the American Society of Haematology Annual Meeting.

**Date: Thursday,  
23rd November 2017**

**12:00pm-1:00pm**

*A light lunch and  
refreshments to follow*

**Location:**  
**TRF Building,**  
**Level 2,**  
**Seminar rooms 1+2**  
27-31 Wright Street,  
Clayton, 3168

